Worldwide Cancer Research
The arrival of COVID-19 changed the world as we knew it. Global priorities underwent seismic shifts and measures to prevent the spread of COVID-19 changed our daily and working lives beyond recognition. In this exclusive interview, we speak with Worldwide Cancer Research’s Director of Research, Dr Lynn Turner, to hear how the pandemic has impacted the ongoing battle against cancer, and what challenges must now be faced as a result.
Could you explain how individuals with cancer have been affected by the pandemic?
We know from reports, studies and analysis conducted over the past year that people with cancer have been heavily impacted by the pandemic. We are concerned that people with cancer are in danger of becoming collateral damage as a result of everyone’s attention being focussed on ‘the other C’ – COVID-19. Across the UK, the pandemic has led to delays in diagnosis and treatment, which researchers estimate could lead to anywhere between 7,000 and 18,000 additional deaths from cancer in 2021. We also saw early in the nationwide lockdown that there was a significant decline in the number of people being referred to emergency cancer services. This is truly worrying and it’s vitally important that people remember to still see their GP if they suspect any sign or symptom of cancer so that they can be referred to a specialist if needed.
How has your work, and research into cancer more generally, been affected by the COVID-19 pandemic?
When the pandemic hit in 2020, we saw a rapid shut down across the world of nearly all our research projects due to university and research institute closures. There were some exceptions, such as in Israel, where our scientists were still able to go to the lab to conduct their research. But even then, they were working at a reduced capacity, with strict social distancing and safety measures in place to protect people.
One thing we felt was important was to make sure that our researchers did not feel pressured in the face of delays caused by lab closures. We offered all our researchers the chance to extend the length of their projects to make up for the lost time. We also allowed the researchers who were just about to start their projects, when the pandemic hit, to delay their start date.
We also had to react quickly internally to shift our annual Big Ideas Gathering, where our Scientific Advisory Committee makes the final decision on which new projects to fund, from a face-to-face meeting to a virtual one. This came with its own set of challenges, but the team did a fantastic job adjusting and we were delighted to be able to make a commitment to fund 16 new projects which will start in 2021.
Can you speculate as to the longer-term consequences of the pandemic for cancer research?
This is a difficult question to speculate an answer to, but we do know that charity-funded medical research is under threat all over the world. In the UK, the sector invested an estimated £1.9 billion in medical research in 2019, which is around half of all publicly funded medical research. The sector is now facing a 40% decrease in medical research spend over the next year and a shortfall of £310 million caused by the impact on fundraising. It’s expected that it will take four and a half years for the sector to recover – something that could have a devastating impact on people diagnosed with cancer in the future.
Despite the significant and unprecedented challenges, what positives have arisen for cancer research over the last year?
COVID-19 undoubtedly slowed scientific research all over the world in 2020, but science has not stopped completely. Scientists supported by Worldwide Cancer Research have contributed to several important breakthroughs in 2020 – including a new cancer vaccine that could enter clinical trials within the next three years and a game-changing treatment for prostate cancer that could be available to patients within four years.
We were also delighted that, thanks to the generosity of our supporters, we were still able to fund new projects this year. We invested over £3.2million in 16 new projects happening in 11 countries around the world. Knowing that we will continue to start new cancer cures gives us, our supporters and people affected by cancer, much-needed hope for the future.
‘…people with cancer are in danger of becoming collateral damage as a result of everyone’s attention being focussed on “the other C” – COVID-19.’
Finally, how can we ensure that cancer research remains a priority in such challenging times?
The type of research Worldwide Cancer Research funds is what we call discovery research. It’s the starting point from which new ways to prevent, diagnose and treat cancer emerge. Without it, we would not have the foundations to build on and we could miss out on future lifesaving discoveries. We must continue to fund this type of research to keep the ideas flowing down the pipeline – now is the time to invest in our future. As we have seen with the amazing response to COVID-19, research is essential to progress. And putting money behind research and those that fund it means that we can make progress faster.
People have woken up to the power of science and research to solve global problems. With 1 in 2 of us in the UK predicted to receive a cancer diagnosis during our lifetime, this is the time to use the momentum we have gained and use it to tackle the ‘big C’.
Reference
https://doi.org/10.33548/SCIENTIA651
Want to republish our articles?
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence
(CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
More articles you may like
AI-Based Video Monitoring of Movement Disorders: Improving Care for Patients with Parkinson’s Disease
As our global population ages, movement disorders like Parkinson’s disease present growing challenges for healthcare systems. Traditional assessment methods rely on subjective clinical ratings during brief clinic visits and often fail to capture the full picture of a patient’s condition. Professor Martin McKeown and his colleagues are pioneering innovative artificial intelligence approaches which use ordinary video recordings to objectively monitor movement disorders. These cutting-edge technologies promise to transform care for millions of patients by enabling remote, continuous assessment of symptoms, while reducing healthcare costs and improving quality of life.
Professor E John List | Tracking Invisible Waters: Predicting the Spread of Contaminated Groundwater Through Underground Aquifers
When we think about water pollution, we often picture oil spills on the ocean surface or chemicals flowing down rivers. But some of the most significant environmental challenges occur completely out of sight, deep underground, where contaminated water moves through layers of rock and soil. Understanding how these invisible pollutants travel has profound implications for protecting our drinking water supplies and coastal ecosystems. Groundwater engineer Dr E. John List has developed an approach that challenges fundamental assumptions about how contamination spreads underground.
Professor Nicola Curtin | Potential for Improving Cancer Treatment by Optimising Drug Scheduling
Cancers often develop because of faulty DNA repair systems. PARP inhibitors (PARPi) are a class of targeted anti-cancer drugs that exploit this weakness, by inhibiting a complementary DNA repair system, to selectively target the tumour. However, these medicines need to be taken every day, creating a burden on patients and reducing the options for combination with other anticancer therapies. Professor Nicola Curtin and her team at Newcastle University investigated how long different PARPi stay active in cancer cells after a single dose and how this influences their effectiveness when combined with another anti-cancer drug.
Dr Richard Marchant | Restoring the Flow: Stream Life Slowly Returns After Rabbit Eradication on Macquarie Island
The remote streams of subantarctic Macquarie Island are home to low diversity freshwater invertebrate communities with an unusual taxonomic composition. However, over a century of grazing by introduced rabbits dramatically degraded surrounding vegetation, increasing erosion and disturbing stream ecosystems. Following rabbit eradication in 2016, Dr Richard Marchant of Museums Victoria and colleagues from the University of Canberra and the Australian Antarctic Division investigated whether the island’s streams were recovering ecologically. Their study reveals a slow but measurable resurgence of invertebrate taxa, particularly in areas with moderate prior damage and vegetation regrowth, though full recovery remains uncertain.